A Randomized, Double-Blind Phase 2 Trial of the CXCRII2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes

Authors
Category Primary study
JournalDIABETES
Year 2020
This article has no abstract
Epistemonikos ID: 352d6345901e88a28e2bcdd980be9fb40b2595d2
First added on: Feb 12, 2025